OncoMatch/Clinical Trials/NCT06904183
Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT
Is NCT06904183 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including LEN+SIN+DEB-TACE+HAIC and LEN+SIN+DEB-TACE for hepatocellular carcinoma non-resectable.
Treatment: LEN+SIN+DEB-TACE+HAIC · LEN+SIN+DEB-TACE — This study is conducted to evaluate the efficacy and safety of lenvatinib plus sintilimab, transarterial chemoembolization (TACE) with drug-eluting beads (DEB-TACE) and hepatic artery infusion chemotherapy (HAIC) with FOLFOX regemen (LEN+SIN+DEB-TACE+HAIC) versus lenvatinib plus sintilimab and DEB-TACE (LEN+SIN+DEB-TACE) for large hepatocellular carcinoma (\> 7cm) with portal vein tumor thrombosis (PVTT).
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: transarterial chemoembolization
previous treatment with TACE
Cannot have received: hepatic arterial infusion chemotherapy
previous treatment with HAIC
Cannot have received: transarterial embolization
previous treatment with TAE
Cannot have received: radiation therapy
previous treatment with radiotherapy
Cannot have received: systemic therapy
previous treatment with systemic therapy
Lab requirements
Blood counts
leukocyte count >3.0×10^9/L, neutrophil count >1.5×10^9/L, platelet count ≥75×10^9/L, hemoglobin 85 g/L
Kidney function
creatinine clearance rate ≤1.5×upper limit of the normal
Liver function
alanine transaminase and aspartate transaminase ≤5×upper limit of the normal; prothrombin time prolongation ≤4 seconds; Child-Pugh class A/B
Cardiac function
organ (heart and kidneys) dysfunction, unable to tolerate TACE or HAIC treatment [excluded]
adequate hematologic and organ function, with leukocyte count>3.0×10^9/L, neutrophil count>1.5×10^9/L, platelet count≥75×10^9/L, hemoglobin 85 g/L, alanine transaminase and aspartate transaminase≤5×upper limit of the normal, creatinine clearance rate≤1.5×upper limit of the normal; prothrombin time prolongation ≤4 seconds; Child-Pugh class A/B; organ (heart and kidneys) dysfunction, unable to tolerate TACE or HAIC treatment [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify